This segment focuses on the research, development, and commercialization of therapies for narcolepsy and related sleep disorders. The primary product in this segment is WAKIX (pitolisant), a medication approved for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. Research and development activities include clinical trials to expand the indications for WAKIX and explore new formulations or delivery methods. The company utilizes advanced pharmaceutical technologies and methodologies to ensure the efficacy and safety of its products. The patient impact is significant, as WAKIX helps improve alertness and reduce EDS, thereby enhancing the quality of life for individuals with narcolepsy. Market positioning is strong due to the unmet medical need and the efficacy of WAKIX. Future opportunities include expanding the label for WAKIX and developing new therapies for other sleep disorders. Regulatory aspects involve ongoing interactions with the FDA and other regulatory bodies to ensure compliance and secure approvals for new indications. Partnerships and collaborations may be pursued to enhance research and commercialization efforts.

This segment encompasses the broader focus on developing and commercializing therapies for rare neurological disorders. Harmony Biosciences is actively involved in research and development to identify and advance treatments for conditions with significant unmet medical needs. This includes exploring new therapeutic targets and conducting clinical trials to evaluate the safety and efficacy of potential treatments. The company leverages its expertise in drug development and commercialization to bring innovative therapies to market. The therapeutic areas covered include, but are not limited to, narcolepsy and potentially other rare neurological conditions. The patient impact is centered on improving the lives of individuals affected by these debilitating disorders. Market positioning is driven by the company's commitment to addressing rare diseases and its ability to navigate the complex regulatory landscape. Future opportunities include expanding the product portfolio and entering new therapeutic areas within rare neurological disorders. Regulatory and clinical aspects involve rigorous clinical trials and interactions with regulatory agencies to ensure the safety and efficacy of the therapies. Partnerships and collaborations with research institutions and other pharmaceutical companies may be pursued to accelerate the development and commercialization of new treatments.